Phase Ib Study of Monoclonal Antibody to OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer After Systemic Therapy
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 24 Jun 2017
At a glance
- Drugs Cyclophosphamide (Primary) ; MEDI 6469 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Jun 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2020.
- 13 Jun 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2018.
- 10 Jun 2017 Biomarkers information updated